MRTX 9768
Alternative Names: MRTX9768Latest Information Update: 25 Jan 2024
At a glance
- Originator Mirati Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 10 Apr 2021 Pharmacodynamics data from a preclinical trial in Cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 10 Mar 2021 MRTX 9768 is available for licensing as of 10 Mar 2021. https://www.mirati.com/contact-us/